Celgene’s (CELG) “Top Pick” Rating Reiterated at Royal Bank of Canada

Celgene (NASDAQ:CELG)‘s stock had its “top pick” rating reiterated by stock analysts at Royal Bank of Canada in a note issued to investors on Tuesday, The Fly reports.

CELG has been the subject of several other reports. Mizuho set a $128.00 price target on Celgene and gave the company a “buy” rating in a report on Tuesday, December 26th. William Blair reiterated an “outperform” rating on shares of Celgene in a report on Friday, October 20th. BTIG Research reiterated a “hold” rating on shares of Celgene in a report on Tuesday. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, Citigroup reiterated a “hold” rating on shares of Celgene in a report on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $129.98.

Shares of Celgene (CELG) traded up $1.64 during trading on Tuesday, hitting $104.55. The stock had a trading volume of 10,416,521 shares, compared to its average volume of 6,990,000. The firm has a market cap of $82,310.00, a price-to-earnings ratio of 24.66, a price-to-earnings-growth ratio of 0.65 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.58 EPS. equities research analysts predict that Celgene will post 6.71 EPS for the current year.

Large investors have recently made changes to their positions in the company. Arcadia Investment Management Corp MI grew its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. grew its holdings in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Robecosam AG acquired a new stake in shares of Celgene during the 3rd quarter worth approximately $114,000. Capital Bank & Trust Co grew its holdings in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares in the last quarter. Finally, Guidant Wealth Advisors acquired a new stake in shares of Celgene during the 3rd quarter worth approximately $119,000. 79.54% of the stock is currently owned by institutional investors.

WARNING: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/23/celgenes-celg-top-pick-rating-reiterated-at-royal-bank-of-canada.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

The Fly

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply